Biotech, medtech, generics — strategic intelligence for decision-makers in the global healthcare sector.
Race for therapeutic innovation, R&D pipeline analysis and anticipation of competitive launches.
Patent expiration, lifecycle management strategies and rise of biosimilars.
Price pressures, negotiations with payers and access strategies in a cost containment context.
Critical dependencies on Asia for active ingredients, relocations and supply security.
Anti-corruption regulations (FCPA, Sapin II), transparency of interests and interactions with HCPs.
Wave of biotech M&A, pipeline acquisitions and reshaping of the pharmaceutical industrial landscape.
Competitive intelligence on laboratory strategies, product launches and market dynamics.
Mapping of competitor R&D pipelines, patent analysis and identification of licensing opportunities.
In-depth audit of acquisition targets: technology, IP, team, commercial potential and regulatory risks.
Strategic support for pharma, biotech and medtech consolidation operations.
Monitoring of FDA, EMA and national agency regulatory developments impacting market authorizations.
Investigations on commercial practices, FCPA/Sapin II compliance and audit of relationships with healthcare professionals.
Big pharma, specialized labs and generics manufacturers
Biotechnology and medical device startups and scale-ups
VC and PE specialized in healthcare, pharma and life sciences
The cabinet operates in this sector. Open a conversation.
Open a conversation